Genomics

Following a record year of profit and growth, the French diagnostics firm secures a major analyst endorsement, signaling a powerful turnaround. What's next?

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

A PIF company becomes the first Saudi entity to join a top global genomics forum, a strategic move under Vision 2030 to shape the future of healthcare.

Genomics leader Francisco De La Vega joins Ultima, signaling a major push to disrupt the inherited disease market with its ultra-low-cost sequencing tech.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

A new book argues modern genomics is stuck on a 'parts list.' Can an architectural approach called 'Deterministic Convergence' build a better future for health?

New research challenges long-held beliefs, revealing a high-risk subset in "safe" tumors and a surprising link between body weight and cancer recurrence.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

Leveraging space-age ferrofluid tech, Ferrotec's new Ferrobeads aim to free labs from costly proprietary systems with a flexible, high-efficiency solution.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

A new powerhouse residency program backed by Silicon Valley elite launches near Stanford to turn academic science into fundable healthcare companies.

A new AI-driven platform moves beyond static reports, offering continuous genomic updates to give cancer patients access to the latest treatment options.

ATCC and the Broad Institute unveil engineered lung cancer cells to decode drug resistance, offering new hope for patients and fueling AI-driven discovery.

A landmark conference merges top organizations to accelerate research on retinal diseases, from gene editing to AI, offering new hope for millions worldwide.

After a decade as Semaphore Solutions, Labbit is going all-in on its LIMS platform. Here’s why the strategic shift matters for regulated laboratories.

A Japanese startup’s ultra-fast genome accelerator joins a national AI program, aiming to slash sequencing time and democratize advanced healthcare.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.